Back to News
Market Impact: 0.3
Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP
Source: marketbeat.com
Healthcare & BiotechProduct Launches
Inovio Pharmaceuticals is approaching the October 30 PDUFA date for INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis. A favorable FDA decision would be a meaningful catalyst for the company, though the article provides no clinical, revenue, or approval-outcome update.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
INO0.20
More News
- Biotech stocks are surging. How investors can play the new drug innovation boom
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- J&J prostate cancer drug shows promising tumor responses in early trial
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine
- Fact vs. fiction: Doctors share whether peptides are safe and effective
- Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer